Halozyme Therapeutics, Inc. Earnings

Halozyme Therapeutics, Inc.’s revenue jumped 35.22% since last year same period to $264.86Mn in the Q1 2025. On a quarterly growth basis, Halozyme Therapeutics, Inc. has generated -11.12% fall in its revenue since last 3-months.

Halozyme Therapeutics, Inc.’s net profit jumped 53.72% since last year same period to $118.1Mn in the Q1 2025. On a quarterly growth basis, Halozyme Therapeutics, Inc. has generated -13.81% fall in its net profits since last 3-months.

Halozyme Therapeutics, Inc.’s net profit margin jumped 13.69% since last year same period to 44.59% in the Q1 2025. On a quarterly growth basis, Halozyme Therapeutics, Inc. has generated -3.02% fall in its net profit margins since last 3-months.

Halozyme Therapeutics, Inc.’s price-to-earnings ratio after this Q1 2025 earnings stands at 14.05.

Halozyme Therapeutics, Inc.’s earning per share (EPS) estimates for the current quarter stand at 0.97 - a -16.12% fall from last quarter’s estimates.

Halozyme Therapeutics, Inc.’s earning per share (EPS) estimates for the current year stand at 0.97.

Halozyme Therapeutics, Inc.’s earning per share (EPS) jumped 40.51% since last year same period to 1.11 in the Q1 2025. This indicates that the Halozyme Therapeutics, Inc. has generated 40.51% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Halozyme Therapeutics, Inc.’s return on assets (ROA) stands at 0.19.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Halozyme Therapeutics, Inc.’s return on equity (ROE) stands at 1.47.